Illumina and PacBio abandon deal
DNA sequencing companies Illumina and Pacific Biosciences have abandoned their proposed $1.2 billion merger, amid increasing antitrust scrutiny in the US and the UK.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.